MTOR and metastatic melanoma: In addition, given that constitutive activation of the PI3K-Akt pathway activates downstream mTOR signalling to drive survival, motility, invasion and proliferation, multiple studies have investigated the use of mTOR inhibitors in combination with other therapies for the treatment of metastatic melanoma patients [recently reviewed in (Chamcheu et al., 2019)].